Adoptive Cell Therapy: Treating Cancer
|
|
- Aldous Watkins
- 5 years ago
- Views:
Transcription
1 Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013
2 Three Main Approaches to Cancer Immunotherapy 1. Non-specific stimulation of immune reactions Stimulate effector cells (IL-2, IL-12) Inhibit regulatory factors (PD-1, CTLA-4) 2. Active immunizations to enhance anti-tumor reactions Cancer vaccines 3. Passively transfer activated immune cells with anti-tumor activity Adoptive cell transfer
3 Advantages of Cell Transfer Therapy 1. High avidity anti-tumor T cell receptors (TCR) can be identified and cloned using in vitro assays. 2. Peripheral blood lymphocytes can be genetically modified to express these high avidity TCRs. 3. Large numbers of tumor-specific lymphocytes can be grown in vitro. 4. The host can be manipulated to provide a favorable tumor microenvironment prior to administering the cells. 5. ACT can mediate tumor regressions.
4 Development of Adoptive Cell Transfer Therapy
5 A Critical Challenge Confronting the Development of Human Cancer Immunotherapy is the Identification of Antigens to Target 1. Differentiation antigens overexpressed on cancers compared to normal tissue (MART-1, gp100, CEA, Her-2, Mesothelin) 2. Antigens expressed on cancers and on non-essential normal tissues (CD19, thyroglobulin) 3. Shared antigens unique to cancer (cancer-testes antigens, NY- ESO-1, MAGE-A) 4. Mutations unique to each cancer (EGFRvIII) 5. Critical components of the tumor stroma (VEGFR2, FAP)
6 Surgery Branch Gene Therapy Products (by class) Cytokine TCR CAR IL-2 IL-12 murine (gp100, NY-ESO-1, MAGE-A3) A3) human (DMF5, NY-ESO-1) 2 nd gen-28z (CD19, Meso) 3 rd gen-28bbz (EGFRvIII, VEGFR2)
7 Interleukin 12 IL-12 is a heterodimeric cytokine, composed of a heavy chain (p40) and a light chain (p35), Coordinated production of the two chains lead to the secretion of the biologically active p70 IL-12 is produced by activated hematopoietic phagocytic cells (monocytes, macrophages, neutrophils) and dendritic cells (DC) Activates effector cells: CD4+, CD8+, and NK cells
8 Development of an Inducible Vector to Mediate IL-12 Production Only in the Tumor Microenviroment MSGV1.NFAT.IL12.PA2 In vitro In vivo No IL 2, no vaccine Zhang L, Kerkar SP et al, Molecular Therapy, 2011
9 Phase I Study of ACT Using TIL Transduced with Gene Encoding IL-12 (9/28, 32% OR) TIL grown for 2-3 weeks Stimulated with OKT-3, transduced and expanded Infuse after Cy/flu preparative regimen No IL-2 administered Cohort Number Result (# cells x 10-9 ) of patients NR NR NR CR (24+ mos); 4NR NR PR (4, 6, 12+) PR (12+); 3NR CR (5+) 3PR (9+, 7, 5) In first 5 cohorts 1 of 17 patients responded. At doses greater than 0.1X10-9, 8 of 11 patients responded.
10 IL-12 Gene Therapy (M.S. 3x107 IL12Td CD8+ TIL)
11 Summary TIL IL-12 Tumor infiltrating i lymphocytes transduced d with NFAT.IL12 vector secrete IL-12 upon stimulation. 28 patients with metastatic melanoma received the autologous TILs genetically modified by NFAT.IL12 vector. Following IL12 Td TILs infusion, 2 patients experienced dose limiting toxicity correlated with high levels of IFN-g and IL-12 in their serum. All patients recovered completely. 9 t f 28 ( 32%) ti t d d t IL 12 Td TIL t t t 9 out of 28 ( 32%) patients responded to IL-12 Td-TIL treatment based on RECIST. IL-2 not needed to achieve OR in this setting.
12 Surgery Branch Gene Therapy Products (by class) Cytokine TCR CAR IL-2 IL-12 murine (gp100, NY-ESO-1, MAGE-A3) A3) human (DMF5, NY-ESO-1) 2 nd gen-28z (CD19, Meso) 3 rd gen-28bbz (EGFRvIII, VEGFR2)
13 T-cell Receptor (TCR) Gene Therapy TCR Cloning IVS Immunize mice TCR Vector (eg, MART1, NY ESO) TCR receptor α β LTR SD Ψ SA TCRα 2A TCRβ LTR CD3ζ,γ,ε,δ
14 Cancer/Testes Antigens - Shared Tumor Specific Antigens Expressed during fetal development Restricted in their expression in adult normal tissues to germ cells Up-regulated in 10-80% of cancers from multiple tissues NY-ESO-1 Family Small family of X-linked genes that includes NY-ESO-1 and LAGE-1 MAGE Family Family of ~ 45 X-linked genes
15 Cancer/Testis Antigens Expressed in Multiple Tumor Types MAGE A3 MAGE A1 NY ESO 1 He Squamous cel Bladder NSCLCC Melanomaa Ovarian patocellular Myeloma ll carcinomaa % of positive tumor by RT PCRR Tumor Type
16 Recognition of Non-melanoma Tumors by NY- ESO-1 TCR Transduced PBL ESO A2 - + Glioblastoma SCLC + + LNZAT3WT4 Ewing s sarcoma TC-71 Glioblastoma LN-18 SCLC NCI H526 Neuroblastoma SKN-AS-A2 MSGIN APB, NY-ESO-1 TCR + + Breast cancer MDA453s-A2 + + Osteosarcoma Saos SCLC + + Melanoma NCI H mel IFN-, pg/ml
17 Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY- ESO-1 TCR-Gene Engineered Lymphocytes J. Clinical Oncology, 29: , 2011
18 DC (Melanoma) CR 30+
19 HK (Synovial Cell Sarcoma) PR (14*)
20 SUMMARY: NY-ESO-1 TCR Engineered T cells TCR gene therapy targeting CTA antigen NY-ESO-1 can lead to cancer regression in melanoma and synovial cell sarcoma without associated toxicities. Total PR CR OR number of patients (duration in months) Melanoma 18 5 (28%) 4 (22%) 9 (50%) (18+,10**, 8, 4, 3) (48+, 37+, 25, 21+**) Synovial Cell (63%) 0 10 (63%) Sarcoma (29+**,14*, 12**,10, 8, 6+, 5, 4, 3**,2+) *treated t twice **plus ALVAC vaccine (Robbins et al J Clin Oncol 29: , 2011)
21 Limitation of TCR gene transfer 1. HLA-restriction limits ability to treat patients / requires multiple TCRs 2. Inability to target lipid / carbohydrate molecules 3. Potential tumor escape via MHC loss / alterations in antigen 3. Potential tumor escape via MHC loss / alterations in antigen processing
22 Surgery Branch Gene Therapy Products (by class) Cytokine TCR CAR IL-2 IL-12 murine (gp100, NY-ESO-1, MAGE-A3) A3) human (DMF5, NY-ESO-1) 2 nd gen-28z (CD19, Meso) 3 rd gen-28bbz (EGFRvIII, VEGFR2)
23 Chimeric Antigen Receptors (CARs) Step 2 Step 1 Step 3 Ig ScFv Linker/TM Antibody Producing Hybridoma Ig Genes T cell signaling Chimeric Antigen Receptor (CAR) CAR (CD19, Meso, EGFRvIII, VEGFR2 CAR receptor LTR sd sa Anti-tumor Ag-scFv CD28 CD3 zeta LTR scfv V L V H V L V H LTR sd sa Anti-tumor Ag-scFv CD8 CD28 4-1BB CD3 zeta LTR CD28 CD3ζ
24 B-Cell Malignancies (Antigens Expressed on Non-Essential Normal Tissues) Approximately 22,000 people die of B-cell malignancies annually in the U.S. CD19 is expressed by more than 90% of B-cell malignancies. CD19 is expressed by mature B cells, B-cell precursors and plasma cells but not any other normal tissues. Anti CD19 CAR 5 LTR FMC63 scfv CD28 CD3 zeta 3 LTR
25 Bone marrow biopsies showed extensive CLL before and nearly absent B-lineage cells after treatment Before treatment 3 months after treatment CD19 CD19 CD20 CD20 Kochenderfer et al. Blood 2012
26 Tumor regression and elimination of normal B cells
27 Patient characteristics and response original patients treated with IL-2 (6/8, 75% OR) Response Number of Number of CAR+ (months since Patient Age/sex Disease prior therapies cells infused/kg infusion) 1a 47/M Follicular 4 0.3x10 7 PR (7) Lymphoma 1b 48/M Follicular 5 1.3x10 7 PR (40+) Lymphoma 2 48/M Follicular 5 0.3x10 7 NE Lymphoma (died of influenza) 3 61/M CLL 3 1.1x10 7 CR (24) 4 55/M Splenic Marginal 3 1.1x10 7 PR (12) Zone Lymphoma 5 54/M CLL 4 0.3x10 7 SD (6) 6 57/M CLL 7 1.7x10 7 PR (7) 7 61/M CLL 4 2.8x10 7 CR (31+) 8 63/M Follicular 7 3.0x10 7 PR (11)* Lymphoma Patient 1 was treated twice. *Patient developed squamous cell carcinoma of the larynx.
28 Response to Therapy with CD19 CAR and No IL-2 (11/14, 78.5% OR) Patient Age/Gender Malignancy Number of prior therapies Total cyclo- Number of Response phosphamide CAR+ T cells (time after cell dose infused infusion in (mg/kg) (X10 6 /kg) months) 1 56/M SMZL PR (20+) 2 43/F PMBCL CR (19+) 3 61/M CLL CR (16+) 4 30/F PMBCL NE 5 63/M CLL CR (10+) 6 48/M CLL CR (7+) 7 42/M DLBCL CR (4+) 8 44/F PMBCL PR (6+) 9 38/M PMBCL SD (1) 10 57/F Low-grade PR (4+) NHL 11 58/F DLBCL from PR (2) CLL 12 60/F DLBCL SD (1+) 13 68/M CLL PR (2+) 14 43/M DLBCL PR (1+)
29 Autologous anti-cd19 CAR-transduced T cell trial conclusions Biological activity of the infused cells was demonstrated by depletion of CD19+ cells 17/22 (77%) evaluable patients obtained remissions, but the contribution of CAR-transduced T cells to the remissions is unclear. Substantial toxicity occurred including hypotension and obtundation. The duration of these toxicities was short. Toxicity correlated with serum levels of inflammatory cytokines.
30 A Critical Challenge Confronting the Development of Human Cancer Immunotherapy is the Identification of Antigens to Target 1. Differentiation antigens overexpressed on cancers compared to normal tissue (MART-1, gp100, CEA, Her-2, Mesothelin) 2. Antigens expressed on cancers and on non-essential normal tissues (CD19, thyroglobulin) 3. Shared antigens unique to cancer (cancer-testes antigens, NY- ESO-1, MAGE-A) 4. Mutations unique to each cancer (EGFRvIII) 5. Critical components of the tumor stroma (VEGFR2, FAP)
31 Program for the Application of Cell Transfer Therapy to a Wide Variety of Human Cancers Receptor Type Cancers Status IL 12 Cytokine Adjuvant for all receptors Accruing MART 1 TCR Melanoma Closed gp100 TCR Melanoma Closed CEA TCR Colorectal Closed 2G1 TCR Renal Accruing Hu NY ESO 1 TCR Epithelial/Sarcoma Accruing Mu NY ESO 1 TCR Epithelial/Sarcoma In development MAGE A3 TCR Epithelial In development SSX 2 TCR Epithelial In development HPV E6/E7 TCR Cervical In development Thyroglobulin TCR Thyroid In development CD19 CAR Lymphomas Accruing VEGFR2 CAR All cancers Accruing EGFRvIII CAR Glioblastoma Accruing Mesothelin CAR Pancreatic/Mesothelioma/Ovarian Accruing CSPG4 CAR Melanoma/Pancreatic/Breast In development
32 Conclusions Autologous peripheral lymphocytes genetically modified to express anti-tumor T cell receptors and chimeric antigen receptors can mediate cancer regression in vivo. The ability to genetically modify human T cells opens possibilities to improve the effectiveness of cell transfer immunotherapy and extend e it to patients with common o epithelial cancers.
33 Personalized immunotherapy using anti-tumor receptor gene-modified lymphocytes
34 Acknowledgments: Surgery Branch, NCI: Steven A. Rosenberg, Chief Rick Morgan Mark Dudley John Wunderlich Paul Robbins James Yang Maria Parkhurst Nick Restifo SBVPF TIL LAB FACS LAB Clinical Staff Lab of Molecular Biology, NCI Ira Pastan Tapan Bera Hematology Branch, NHLBI Dhana Chinnasamy ETIB, NCI Jim Kochenderfer Pediatric Oncology Branch, NCI Ling Zhang NYU Langone Medical Center Howard Fine
DEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationTrial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor
Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,
More informationTumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More informationNIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12.
NIH Public Access Author Manuscript Published in final edited form as: Science. 2006 October 6; 314(5796): 126 129. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard
More informationFunctional reprogramming of the tumor stroma by IL-12 Engineered T cells is required for anti-tumor immunity. Sid Kerkar, M.D.
Functional reprogramming of the tumor stroma by IL-12 Engineered T cells is required for anti-tumor immunity Sid Kerkar, M.D. Cancer Therapies Surgery Chemotherapy Radiation Emerging Cell Based Therapy
More informationAdoptive Cellular Therapy SITC Primer October 2012
Adoptive Cellular Therapy SITC Primer October 2012 Cassian Yee MD Member Fred Hutchinson Cancer Research Center Program in Immunology Clinical Research Division Professor University of Washington Division
More informationCBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology
CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology Peter Bross, MD Office of Cellular, Tissue and Gene Therapies, CBER FDA IOM Policy Issues in the Clinical Development
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationMelanoma Bridge Meeting
Melanoma Bridge Meeting Improving Adoptive Immune Therapy with Genetically Engineered T cells David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH 3 December 2015 Adoptive T Cell Therapy: Dose
More informationAdvances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014
Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus
More informationSTATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)
STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) Topics for Consideration What are the rules for integrating
More informationOverview 3/31/2016. Cell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationCell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH 1 Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationCorporate Presentation
Corporate Presentation June 2017 Forward-Looking Statements This presentation contains forward-looking statements reflecting management s current beliefs and expectations. These forward looking statements
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationEngineered TCR and CAR Immunotherapeutics 2015:
: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs and CTLs released by La Merie Publishing on March 10, 2015 La Merie Publishing
More information- Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases.
암의면역치료 권병세 Immunotheraphy - Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases. - Applied for the treatment of cancer, autoimmune diseases, transplant rejection,
More informationAdoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016
Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016 Leila Khoja 1,2 and Bishal Gyawali 3 1 Royal Free Hospital, Pond Street, London NW3 2QG, UK. 2 Astrazeneca
More informationCell Therapies. John HaanenMD PhD
Cell Therapies John HaanenMD PhD My disclosures I have provided consultation, attended advisory boards, and/or provided lectures for: Pfizer, Bayer, MSD, BMS, IPSEN, Novartis, Roche/Genentech, Astra Zeneca/MedImmune,
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationPrecision CAR T Cell Therapeutics. Carl June October 15, 2018
Precision CAR T Cell Therapeutics Carl June October 15, 2018 Disclosure Information Carl June I have the following financial relationships to disclose: Consultant for: Novartis, Immune Design, Viracta,
More informationBASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION
BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION Zihai Li, M.D., Ph.D. Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC) DISCLOSURE GOALS Understand that immune
More informationConcepts of cancer immunotherapy
Concepts of cancer immunotherapy History Paul Ehrlich first conceived the idea that tumor cells can be recognized as foreign and eliminated by the immune system. Subsequently, Lewis Thomas and Macfarlane
More informationCAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability. Julie M. Vose, MD, MBA
CAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability Julie M. Vose, MD, MBA Relevant Disclosures Research Funding: Kite Pharma/Gilead, JUNO/Celgene, Novartis Honorarium/Ad Boards: Novartis,
More informationCo-ordinating Genetically Engineered Adoptive Cell-Based Immunotherapies - Immune Cells That Can Be Hijacked and Programmed to Target Cancer
1 Co-ordinating Genetically Engineered Adoptive Cell-Based Immunotherapies - Immune Cells That Can Be Hijacked and Programmed to Target Cancer ADOPT SUMMIT 2016 2 nd March 2016 London Cedrik Britten DISCLAIMER
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationAdoptive T Cell Therapy TILs & TCRs & CARs
Adoptive T Cell Therapy TILs & TCRs & CARs Inge Marie Svane CCIT DENMARK Professor, MD Center for Cancer Immune Therapy Department of Oncology, Herlev Hospital Copenhagen University Denmark Therapeutic
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationAN OVERVIEW OF CELLULAR THERAPY
AN OVERVIEW OF CELLULAR THERAPY Nicole Aqui, M.D. Chief, Transfusion and Apheresis Services Division of Transfusion Medicine Department of Pathology and Laboratory Medicine University of Pennsylvania Conflict
More informationImmunotherapy of Prostate Cancer
Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines
More informationThe immune response against cancer
The immune response against cancer Maries van den Broek Institute of Experimental Immunology vandenbroek@immunology.uzh.ch The immune system Main cells of the immune system Dendritic cell Monocyte Macrophage
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationCancer Immunotherapy INTRODUCTION HUMAN TUMOR ANTIGENS. Cancer/Germ-Line Antigens
14 Cancer Immunotherapy Steven A. Rosenberg, Paul R. Robbins, Giao Phan, Steven Feldman, and James Kochenderfer INTRODUCTION Progress in understanding basic aspects of cellular immunology and tumor host
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationOverview 4/11/2013. Cell Kinetics in Adoptive Cell Therapy. April 11, 2013
Cell Kinetics in Adoptive Cell Therapy April 11, 2013 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationRichard P Junghans, PhD, MD
CANCER GENE THERAPY WITH DESIGNER T CELLS: TOXICITY VERSUS ACTIVITY Richard P Junghans, PhD, MD Director, Biotherapeutics Development Lab Associate Professor of Surgery and Medicine Boston University School
More informationCancer Immunotherapy. What is it? Immunotherapy Can Work! 4/15/09. Can the immune system be harnessed to fight cancer? T CD4 T CD28.
Cancer Immunotherapy CANCER BIOLOGY April 15, 2009 Can the immune system be harnessed to fight cancer? Can the immune system see cancer? What is the best way to turn on the immune system to fight cancer?
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationDriving gene-engineered T cell immunotherapy of cancer
REVIEW Cell Research (2017) 27:38-58. 2017 IBCB, SIBS, CAS All rights reserved 1001-0602/17 $ 32.00 www.nature.com/cr Driving gene-engineered T cell immunotherapy of cancer Laura A Johnson 1, Carl H June
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationThe Adaptive Immune Response. T-cells
The Adaptive Immune Response T-cells T Lymphocytes T lymphocytes develop from precursors in the thymus. Mature T cells are found in the blood, where they constitute 60% to 70% of lymphocytes, and in T-cell
More informationCurrent Tumor Immunotherapy
Current Tumor Immunotherapy Part 1: On the preclinical and clinical efficacy of the current cancer vaccines. Part 2: The critical role of cancer vaccines in new integrative approaches. The State of the
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationTodd D. Prickett Ph.D. Surgery Branch/NCI/NIH. Dr. Steven A. Rosenberg Branch Chief Dr. Paul F. Robbins Surgery Branch/NCI/NIH
Durable Complete Response in a Patient with Metastatic Melanoma Following Adoptive Transfer of Autologous T cells Recognizing 1 Mutated Tumor Antigens Todd D. Prickett Ph.D. Surgery Branch/NCI/NIH Dr.
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationChildren s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant
Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179
More informationSociety for Immunotherapy of Cancer (SITC)
Society for Immunotherapy of Cancer (SITC) Current Status of Chimeric and Adoptive T cell Therapy Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy
More informationEngineered T cells: the promise and challenges of cancer immunotherapy
Engineered T cells: the promise and challenges of cancer immunotherapy Andrew D. Fesnak, Carl H. June and Bruce L. Levine Abstract The immune system evolved to distinguish non-self from self to protect
More informationT Cell Development. Xuefang Cao, MD, PhD. November 3, 2015
T Cell Development Xuefang Cao, MD, PhD November 3, 2015 Thymocytes in the cortex of the thymus Early thymocytes development Positive and negative selection Lineage commitment Exit from the thymus and
More informationAdoptive T Cell Therapy:
Adoptive T Cell Therapy: A Paradigm for Combination Strategies Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy
More informationEngineered T cells: Next-generation cancer immunotherapy
Engineered T cells: Next-generation cancer immunotherapy Rahul Purwar, Assistant Professor Department of Biosciences & Bioengineering Indian Institute of Technology Bombay (IIT Bombay) Mumbai, India, 400076
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationMarshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011
Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Most common form of cancer in adults ages 25-29 3-5% of skin cancers but 65-75% of deaths Most common metastasis to small
More informationFour main classes of human tumor antigens recognized by T cells: 1- "Cancer-testis" antigens: non-mutated genes reactivated in neoplastic cells, but
Tumor antigens Andrea Anichini Human Tumors Immunobiology Unit, Dept. of Experimental Oncology and Molecular Medicine Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Timeline of the discovery of
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationAdoptive Immunotherapy
Adoptive Immunotherapy Policy Number: 8.01.01 Last Review: 10/2018 Origination: 12/2015 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Adoptive
More informationUniversity of Lausanne and Ludwig Institute
T Cell Adoptive Therapy Approaches, Challenges and Solutions for Beating Cancer George Coukos, MD, PhD University of Lausanne and Ludwig Institute Examples of Clinical Studies Targeting Solid Tumors
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationSupplemental Table I.
Supplemental Table I Male / Mean ± SEM n Mean ± SEM n Body weight, g 29.2±0.4 17 29.7±0.5 17 Total cholesterol, mg/dl 534.0±30.8 17 561.6±26.1 17 HDL-cholesterol, mg/dl 9.6±0.8 17 10.1±0.7 17 Triglycerides,
More informationFuture Directions in Immunotherapy
Future Directions in Immunotherapy Naiyer Rizvi, MD Price Chair, Clinical Translational Medicine Director of Thoracic Oncology Director of Immuno-Oncology Columbia University Medical Center New York, New
More informationCAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris
CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationHistorical overview of immunotherapy
Historical overview of immunotherapy Before introduction of immune checkpoint inhibitors John B.A.G. Haanen, MD PhD My Disclosures I have provided consultation, attended advisory boards, and/or provided
More informationThe next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)
The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold
More information